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Background: Secondary prophylaxis of stroke without atrial fibrillation or artificial heart valves remains challenging. Multiple randomized control 
trials evaluating warfarin with or without aspirin after the first incidence of coronary artery disease (CAD) or cerebrovascular disease (CVD) have 
yielded mixed results.
Methods: Meta-analysis of the literature (MEDLINE - 1980 to August 2010) was performed to determine pooled estimates of benefits (reduced 
incidence of stroke) and risks (mortality, intracranial bleeds, major and minor bleeds) of warfarin (with and without aspirin) in patients with CAD and 
CVD. 24 trials (32827 patients) were stratified based on the intensity of the therapeutic international normalized ratio (INR): low (INR3.0).
Results: In patients with CAD, intermediate intensity warfarin with aspirin when compared to aspirin alone, significantly reduced risk of secondary 
strokes [relative risk (RR) 0.48, confidence interval (CI) 95% 0.29-0.80], increased the risk of intracranial (RR 3.03 CI 95% 0.48-19.20) and major 
bleed (RR 2.54, CI 95% 1.70-3.79) and did not reduce mortality (RR 1.00, CI 95% 0.80-1.25). Intermediate intensity warfarin without aspirin did not 
reduce stroke compared to aspirin alone (RR 1.16, CI 95% 0.46-2.93). In patients with CVD, intermediate intensity warfarin without aspirin although 
did reduce stroke, but did not reach statistical significance (RR 0.78, CI 95% 0.55-1.11) and modestly increased the risk of intracranial (RR 1.81, CI 
95% 0.87-3.77) and major (RR 2.27, CI 95% 1.52-3.37) bleed. There are no studies of intermediate intensity warfarin plus aspirin in this population. 
Low intensity warfarin did not confer any additional benefit with previous CVD. High intensity warfarin increased intracranial (RR 14.30, CI 95% 1.89-
108.44) bleed substantially.
Conclusions: In CAD patients, use of intermediate intensity warfarin with aspirin reduces the risk of stroke at the price of increased bleeding. In 
CVD patients, intermediate intensity warfarin without aspirin also reduced stroke. Intermediate intensity warfarin plus aspirin might be particularly 
effective for secondary prevention in CVD patients.
